Warning: The NCBI web site requires JavaScript to function. more...
Molecular biology of breast cancer metastasis. Inflammatory breast cancer: clinical syndrome and molecular determinants.
Kleer CG, van Golen KL, Merajver SD.
Breast Cancer Res. 2000;2(6):423-9. Epub 2000 Jul 11. Review.
Related citations
Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.
Yu H, Levesque MA, Clark GM, Diamandis EP.
Br J Cancer. 1999 Oct;81(3):490-5.
Metaplastic carcinoma of the breast: analysis of eight Asian patients with special emphasis on two unusual cases presenting with inflammatory-type breast cancer.
Kuo SH, Chen CL, Huang CS, Cheng AL.
Anticancer Res. 2000 May-Jun;20(3B):2219-22. Review.
Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes.
Habibi G, Leung S, Law JH, Gelmon K, Masoudi H, Turbin D, Pollak M, Nielsen TO, Huntsman D, Dunn SE.
Breast Cancer Res. 2008;10(5):R86. Epub 2008 Oct 16.
[Effect of the proliferation rate on the course of node negative breast carcinoma].
Mitze M, Weikel W, Brumm C, Lippold R, Knapstein PG.
Geburtshilfe Frauenheilkd. 1995 Jun;55(6):299-305. German.
Evaluation of serum HER2 extracellular domain in early breast cancer patients: correlation with clinicopathological parameters and survival.
Ludovini V, Gori S, Colozza M, Pistola L, Rulli E, Floriani I, Pacifico E, Tofanetti FR, Sidoni A, Basurto C, Rulli A, Crinò L.
Ann Oncol. 2008 May;19(5):883-90. Epub 2008 Jan 10.
WISP3 is a novel tumor suppressor gene of inflammatory breast cancer.
Kleer CG, Zhang Y, Pan Q, van Golen KL, Wu ZF, Livant D, Merajver SD.
Oncogene. 2002 May 9;21(20):3172-80.
The impact of induction duration and the number of high-dose cycles on the long-term survival of women with metastatic breast cancer treated with high-dose chemotherapy with stem cell rescue: an analysis of sequential phase I/II trials from the Dana-Farber/Beth Israel STAMP program.
Elias AD, Ibrahim J, Richardson P, Avigan D, Joyce R, Reich E, McCauley M, Wheeler C, Frei E 3rd.
Biol Blood Marrow Transplant. 2002;8(4):198-205.
Elevated chemokine receptor CXCR4 expression in primary tumors following neoadjuvant chemotherapy predicts poor outcomes for patients with locally advanced breast cancer (LABC).
Holm NT, Abreo F, Johnson LW, Li BD, Chu QD.
Breast Cancer Res Treat. 2009 Jan;113(2):293-9. Epub 2008 Feb 13.
Mitogen activated protein kinase pathway is involved in RhoC GTPase induced motility, invasion and angiogenesis in inflammatory breast cancer.
van Golen KL, Bao LW, Pan Q, Miller FR, Wu ZF, Merajver SD.
Clin Exp Metastasis. 2002;19(4):301-11.
Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.
Adv Exp Med Biol. 2007;608:1-22. Review.
A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study.
Novelli F, Milella M, Melucci E, Di Benedetto A, Sperduti I, Perrone-Donnorso R, Perracchio L, Venturo I, Nisticò C, Fabi A, Buglioni S, Natali PG, Mottolese M.
Breast Cancer Res. 2008;10(5):R74. Epub 2008 Sep 4.
Prognostic impact of human epidermal growth factor-like receptor 2 and hormone receptor status in inflammatory breast cancer (IBC): analysis of 2,014 IBC patient cases from the California Cancer Registry.
Zell JA, Tsang WY, Taylor TH, Mehta RS, Anton-Culver H.
Breast Cancer Res. 2009;11(1):R9. Epub 2009 Feb 19.
Defining the molecular biology of inflammatory breast cancer.
Charafe-Jauffret E, Tarpin C, Viens P, Bertucci F.
Semin Oncol. 2008 Feb;35(1):41-50. Review.
High prevalence of HER-2/neu and p53 overexpression in inflammatory breast cancer.
Sawaki M, Ito Y, Akiyama F, Tokudome N, Horii R, Mizunuma N, Takahashi S, Horikoshi N, Imai T, Nakao A, Kasumi F, Sakamoto G, Hatake K.
Breast Cancer. 2006;13(2):172-8.
Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome.
Arpino G, Bardou VJ, Clark GM, Elledge RM.
Breast Cancer Res. 2004;6(3):R149-56. Epub 2004 Feb 17.
Transfected MCF-7 cells as a model for breast-cancer progression.
Kern FG, McLeskey SW, Zhang L, Kurebayashi J, Liu Y, Ding IY, Kharbanda S, Chen D, Miller D, Cullen K, et al.
Breast Cancer Res Treat. 1994;31(2-3):153-65. Review.
Inflammatory breast cancer (IBC) and patterns of recurrence: understanding the biology of a unique disease.
Cristofanilli M, Valero V, Buzdar AU, Kau SW, Broglio KR, Gonzalez-Angulo AM, Sneige N, Islam R, Ueno NT, Buchholz TA, Singletary SE, Hortobagyi GN.
Cancer. 2007 Oct 1;110(7):1436-44.
Prognostic significance of vascular endothelial growth factor D in breast carcinoma with long-term follow-up.
Nakamura Y, Yasuoka H, Tsujimoto M, Yang Q, Imabun S, Nakahara M, Nakao K, Nakamura M, Mori I, Kakudo K.
Clin Cancer Res. 2003 Feb;9(2):716-21.
Update on inflammatory breast cancer.
Lerebours F, Bieche I, Lidereau R.
Breast Cancer Res. 2005;7(2):52-8. Epub 2005 Jan 20. Review.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on